Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions

Download our infectious disease white paper on innovative clinical trial technologies

White paper: Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases

Antimicrobial resistance can facilitate the emergence of new or previously recognized disease agents, and its damaging effects are increasingly being seen around the world.
download

 This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola and the extensive capabilities QSolutions offers in support of infectious disease clinical trials, including:
  • Niche and novel assay developmentInfectious Disease
  • DNA & RNA extraction and next-generation sequencing
  • Integrated local lab data management services
  • Global laboratory network held to rigorous quality standards and biosafety protocols

Read more about how we are applying innovative technologies to provide customers insights into developing diagnostics and therapies with enhanced efficacy against the target pathogens and their resistant variants for improved safety.

Authors:

Ayaskant PanyAyaskant Pany, MD
Director, Medical Laboratory, Central Laboratories South Africa, Q2 Solutions, a Quintiles Quest Joint Venture   

Dr. Pany is currently the Medical Laboratory Director, South Africa. His broad responsibilities include both administrative and technical management of the laboratory and its employees. He also oversees developmental activities for TB and microbiology at Q2 Solutions. Read Dr. Pany’s insightful perspectives on World TB Day.


Sorika van NiekerkSorika van Niekerk, MSc, UP, SA
Senior Director/General Manager, Central Laboratories South Africa, Q² Solutions, a Quintiles Quest Joint Venture

Sorika van Niekerk is senior director of laboratory operations for Sub-Saharan Africa with a special interest and specific strategy to increase the infectious disease footprint for the laboratory.



Stephen MortlockStephen Mortlock, DSc.

Global Infectious Diseases and Microbiology Laison, Q2 Solutions, a Quintiles Quest Joint Venture 

Dr. Stephen Mortlock is the Global Infectious Diseases and Microbiology Liaison at a Q2 Solutions laboratory in the UK.  




Wayne HogrefeWayne R. Hogrefe, Ph.D., D (ABMLI)
Vice President, Vaccine unit, Q2 Solutions, a Quintiles Quest Joint Venture Company

Dr. Hogrefe is the vice president of the vaccine unit at Q2 Solutions, a Quintiles Quest Joint Venture, where he has had overall business development responsibilities for the past eight years